3-Methoxychrysazin suppresses RANKL-induced osteoclastogenesis by modulating Notch2 signaling.
Findings indicate that 3-MC mitigates osteoclast differentiation and oxidative stress, accompanied by downregulation of the Notch2 signaling axis, highlighting its potential as a promising therapeutic candidate for bone-related disorders.